Shanghai Henlius Biotech (HKG:2696) secured an implied approval for the phase 2/3 clinical trial of HLX43 for injection in Japan by the country's Pharmaceuticals and Medical Devices Agency, according to a Monday Hong Kong bourse filing.
The drug is being tested as monotherapy or in combination with pimurutamab HLX07 versus Docetaxel for advanced squamous non-small cell lung cancer.
The firm will begin the trial once the relevant conditions are fulfilled, the filing said.
Three-wheeler manufacturer Atul Auto's (NSE:ATULAUTO, BOM:531795) total sales jumped 74% to 3,001 units in April from 1,725 units sold a year ago, according to a Friday filing to the Indian stock exchanges.Of the total, domestic sales grew sharply year-on-year to 2,478 units in April from 1,427 units.
Leader Education (HKG:1449) booked 20.2 million yuan in attributable profit for the fiscal first half ended Feb. 28, down 17% from 24.2 million yuan a year earlier, according to a Hong Kong bourse filing Sunday.The higher education services company's shares fell nearly 2% in morning trade Monday.Earnings per share were 0.0303 yuan, compared with 0.0363 yuan in the prior-year period.Revenue rose 11% year on year to 191.3 million yuan, figures showed.
CSL (ASX:CSL) led losses on the Australian bourse so far this year at AU$23.2 billion, while ResMed (ASX:RMD) and Cochlear (ASX:COH) followed with losses of AU$10.6 billion, the Australian Financial Review reported Monday, citing Global X ETFs.Negative performing companies on the S&P/ASX 200 index collectively wiped out over AU$217 billion, said Marc Jocum, senior product and investment strategist at Global X ETFs.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)